Article PDF
Avoid common mistakes on your manuscript.
Literatur NSAID
Blum AL, Bolten WW, Labenz J, et al. Therapie und Prävention des ASS- und NSAR-Ulkus. Dtsch Ärztebl 1998;95:348–54.
Brune K, Hinz B. Selektive Cyclooxygenase-2-Hemmer: Glaube, Hoffnung, Realität. Aktuel Rheumatol 1998;23:1–5.
Brune K, Hinz B.: Zum aktuellen Stand der Zyklooxygenaseforschung. Dtsch Ärztebl 1998;95:343–6.
Brune K, Glatt M, Graf P. Mechanism of action of inflammatory drugs. Gen Pharmacol 1976;7:27–33.
Frölich JC. Pharmakologische Wirkungen von antiphlogistischen Substanzen auf den Knorpel. Z Rheumatol 1998;57:185.
Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737–40.
Geis GS, Stead H, Morand S, et al. Efficacy and safety of celecoxib, a specific Cox-2 inhibitor in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl: 1699.abstract.
Gonzales E, de la Cruz C, de Nicola’s R. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agent Actions 1994;41:171–8.
Herschman HR. Prostaglandin-Synthase 2. Biochim Biophys Acta 1996;1299:125–40.
Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with Misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727–34.
Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (Celecoxib), a novel Cox-2 selctive inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 1996;39:Suppl:1188.abstract.
Martel-Pelletier J, Cloutier J-M, Pelletier J-P. Effects of aceclofenac and Ddiclofenac on synovial inflammatory factor in human osteoarthritis. Clin Drug Invest 1997;14:226–32.
Sano H, Hashiramoto A, Yamada R, et al. Treatment of rheumatoid arthritis and rat adjuvant-induced arthritis by cyclooxygenase-2 antisense through induction of apoptosis. Arthritis Rheum 1998;41:Suppl:772.abstract.
Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum 1998;41:1591–602.
Stichenroth D, Zeidler H, Frölich J. Neue nichtsteroidale Antirheumatika: Selektive Hemmstoffe der induzierbaren Cyclooxygenase. Med Klin 1998;93:407–15.
Tugwell P, Ortiz Z, Griffith B. Rheumatoid arthritis: Emerging evidence for the benefits of early and aggressive therapy. Dis Managem Hlth Outcomes 1997;3:141–53.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971;231 232–5.
Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with Rranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719–26.
Literatur Glucocorticoide
American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations of the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791–01.
Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997;56:27–31.
Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids. Inhibition of NF-kB activity through induction of IkBa synthesis. Science 1995;270:286–90.
Bamberger CM, Schulte HM. Wirkungsmechanismus der Glucocorticoide. Internist (Berlin) 1997;38:366–70.
Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200–57.
Boumpas DT, Paliogianni F, Anastassiou ED, et al. Glucocorticosteroid action of the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991; 9:413–23.
Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961–8.
Civitelli R. The role of vitamin D metabolites in the treatment of osteoporosis. Calcif Tissue Int 1995;57:409–14.
Cortet B, Flipo RM, Blanckaert F, et al. Evalution of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed 1997;64:451–8.
Crofford LJ, Kalogeras KT, Mastorakos G, et al. Circadian relationship between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones. Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279–83.
Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996;35:309–22.
Dequeker J, Maenaut K, Verwilghen J, et al. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 1995;13:Suppl 12:S21–6.
Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39:396–402.
Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23–7.
Goulding NJ, Godolphin JL, Sharland PR, et al. Anti-inflammatory lipocortin 1 is produced by peripheral blood leucocytes in response to intravenous hydrocortisone. Lancet 1990;335:1416–9.
Goulding NJ. Corticosteroids — a case of mistaken identity? Br J Rheumatol 1998;37:477–80.
Gudbjornsson B, Skogseid B, Oberg K, et al. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J Rheumatol 1996;23:596–602.
Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-a secretion. Inflamm Res 1997;46:447–51.
Kirwan JR, ARC Low-dose Glucocorticoid Study Group. The effect of glucocorticoid and joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142–6.
Kirwan JR, Kim KK. Low dose corticosteroids in early rheumatoid arthritis: Can these drugs slow disease progression? Drugs Aging 1996;8:157–61.
Masi AT, Chrousos GP. Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis 1997;56:1–4.
McGill PE, Kerr H, Stirling A. Effect of cyclical etidronate on BMD insteroid treated RA. Bone 1997;20:Suppl:S99.
Oelzner P, Müller A, Deschner F, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193–8.
Oelzner P, Hein G. Entzündung und Knochenstoffwechsel bei rheumatoider Arthritis — Pathogenetische Gesichtspunkte und therapeutische Möglichkeiten. Med Klin 1997;92:607–14.
Peel NF, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801–6.
Ringe JD. Generalisierte Osteoporose bei chronischer Polyarthritis — Pathomechanismen und Behandlungsansätze. Z Rheumatol 1996;55:149–57.
Saag KG, Criswell LA, Sems KM, et al. Low dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996; 39:1818–25.
Sambrook P, Birmingham J, Kelly, P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328:1747–52.
Sambrook PN, Jones J. Corticosteroid osteoporosis. Br J Rheumatol 1995;34:8–12.
Scheinman RI, PC Cogswell, Lofquist AK, et al. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283–6.
Stichtenoth DO, Frolich JC. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 1998;37:246–57.
Tarbadel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76–80.
Verstraeten A, Dequeker J, Nijs J, et al. Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two year prospective study. Clin Exp Rheumatol 1989;7:351–8.
Literatur Basisterapie
American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713–22.
Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a doubleblind placebo-controlled study. Br J Rheumatol 1996;35:1142–9.
Burkhardt H, Kalden J. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 1997;17:85–90.
Chaudhuri K, Torley H, Madhok R. Cyclosporin. Br J Rheumatol 1997; 36:1016–21.
Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). Arthritis Rheum 1996; 39:2021–7.
Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004–12.
Egsmose C, Hansen TM, Andersen LS, et al. Limitid effect of sulfasalzine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis 1997;56:32–6.
Flipo RM, Emery P, Scott DG, et al. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis. J Rheumatol 1998;25:1263–9.
Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;53:Suppl:20–6.
Jones G, Crotty M, Brooks P, The Psoriatic Arthritis Meta-Analysis Study Group. Psoriatic arthritis: A quantitative overview of therapeutic options. Br J Rheumatol 1997; 36:95–9.
Li E, Brooks P, Conaghan PC. Disease-modifying antirheumatic drugs. Curr Opin Rheumatol 1998; 10:159–68.
Lorenz HM, Geiler T, Kalden JR. Immunsuppressive Therapiemodalitäten bei chronischen Polyarthritiden. Internist (Berlin) 1997;38:532–40.
Moreland LW, Fleischmann RM, for the Leflunomide RA Investigators Group and Strand V. Efficacy of lefluomide vs placebo vs methotrexate in early and late rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl:S155.
Olivieri I, Salvarani C, Cantini F, et al. Therapy with cyclosporin in psoriatic arthritis. Semin Arthritis Rheum 1997;27:36–43.
Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006–15.
Rau R, Furst DE, Menninger H, et al. Kombinationstherapie bei chronischer Polyarthritis. Z Rheumatol 1998;57:17–49.
Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators Group. J Rheumatol 1998;53:Suppl:27–32.
Schnülle P, van der Woude FJ Mycophenolat Mofetil im Vergleich zu anderen Immunsuppressiva. Internist (Berlin) 1998;39:879–86.
Smolen JS, Kalden JR, Scott DL, et al. the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalzine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–66.
Somerville MF, Scott DG. Neoral-new cyclosporin for old? Br J Rheumatol 1997;36:1113–5.
Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997;40:1843–51.
Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137–41.
van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493–8.
Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612–9.
Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37:874–82.
Zink A, Listing J, Gu F, et al., Modellverbund BMG-geförderter Rheumazentren. Rheumatologische Kerndokumentation in der BMG-geförderten Rheumazentren im Jahr 1995. Deutsches Rheuma-Forschungszentrum Berlin. Forschungsbereich Epidemiologie. Epi-Report No 6, Berlin, Juli 1997.
Literatur Antizytokintherapie
Alsalameh S, Kalden JR, Burmester GR. Die Rolle von Zytokinen und Wachstumsfaktoren bei der rheumatoiden Gelenkdestruktion. Z Rheumatol 1991;50:347–59.
Bresnihan B, on behalf of the collaborating investigators, Lookabaugh J, Witt K, Mukisic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhulL-1ra) in rheumatoid arthritis: Results of a randomized double-blind, placebo-controlled multicenter study. Arthritis Rheum 1996;39:Suppl 9:73.
Burmester GR, Manger B, Kalden J. Immunpathogenese entzündlich-rheumatischer Erkrankungen. Dtsch Ärztebl 1995;92:1010–20.
Chu CQ, Field M, Feldmann M, et al. Localization of tumour necrosis factor a in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125–32.
Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthritis Rheum 1993; 36:1681–90.
Elliot MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996;8:195–200.
Kalden-Nemeth D, Grebmeier J, Antoni C, et al. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int 1997;16:249–55.
Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by i. v. infusion of a chimeric, monoclonal TNF-alpha natibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646–53.
Maini RN. Monoclonal anti-TNFa antibody (cA2) in the treatment of rheumatoid arthritis. In: Feng PH, ed. Proc of the XIXth ILAR Congress of Rheumatology. Singapore: Communication Consultants, 1997:459–64.
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334–42.
Salfeld J, Kaymakçalan Z, Tracey D, et al. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998; 41:S57.
Schattenkirchner M, Krüger, K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis — results of a phase I study. Arthritis Rheum 1998; 41:S57.
van de Putte L, van Riel P, den Broeder A, et al. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S57.
Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253–9.
Weinblatt ME, Moreland LW, Schiff MH, et al. Longterms and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75-Fc-fusion protein (TNF:Fc:ENBRELTM). Arthritis Rheum 1997; 40:S59.
Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hein, G., Eidner, T., Oelzner, P. et al. Update Rheumatologie — Teil II. Med Klin 94, 556–563 (1999). https://doi.org/10.1007/BF03044953
Issue Date:
DOI: https://doi.org/10.1007/BF03044953